Response of OVCAR-3 Cells to Cisplatin and Hyperthermia: Does Hyperthermia Really Matter?

• Published in: Anticancer research Vol. 37; no. 9; pp. 5011 - 5018
• Main Authors: Sukovas, Arturas, Cesna, Vaidotas, Jasukaitiene, Aldona, Barauskas, Giedrius, Nadisauskiene, Ruta Jolanta, Dambrauskas, Zilvinas, Paskauskas, Saulius, Gulbinas, Antanas
• Format: Journal Article
• Language: English
• Published: Greece 01-09-2017
• Subjects: Antineoplastic Agents - pharmacology; Apoptosis; Cell Proliferation; Cisplatin - pharmacology; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Ovarian Neoplasms - pathology; Ovarian Neoplasms - therapy; Tumor Cells, Cultured; OVCAR-3; hyperthermia; HIPEC; cisplatin; Epithelial ovarian cancer
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.11915

Hyperthermic intraperitoneal chemotherapy (HIPEC) is proposed as a promising treatment method, but fundamental information about the contribution of hyperthermia to intraperitoneal chemotherapy is lacking. The purpose of this study was to investigate the cytotoxic effect of hyperthermia and cisplatin on OVCAR-3 cells in vitro.
Imitating the typical clinical conditions of HIPEC, OVCAR-3 cells were exposed to hyperthermia and cisplatin for 1 h. MTT viability test, flow cytometric analysis, and real-time cell and isobologram analysis were performed.
Hyperthermia up to 42°C did not significantly increase the effect of cisplatin regarding the viability and apoptosis of OVCAR-3 cells. Moreover, an antagonistic effect of hyperthermia and cisplatin was revealed.
Our investigation of OVCAR-3 cells critically disputes the benefit of hyperthermia in ovarian cancer treatment. Further in vitro and in vivo research is essential for better understanding of the mechanisms of action of hyperthermia and its role in the treatment of epithelial ovarian cancer.